A year of successful cancer vaccines points to a path forward.
Publication
, Journal Article
Morse, MA; Whelan, M
Published in: Curr Opin Mol Ther
February 2010
Results from recent clinical trials of the therapeutic vaccines sipuleucel-T (Dendreon Corp), PROSTVAC-VF-TRICOM (National Cancer Institute/BN ImmunoTherapeutics Inc) and BiovaxID (Biovest International Inc) are highlighted. These data support the further development of such vaccines, and provide guidance for the development of improved agents and protocols for the use of therapeutic vaccination to treat cancer.
Duke Scholars
Published In
Curr Opin Mol Ther
EISSN
2040-3445
Publication Date
February 2010
Volume
12
Issue
1
Start / End Page
11 / 13
Location
England
Related Subject Headings
- United States
- Prostatic Neoplasms
- Neoplasms
- National Cancer Institute (U.S.)
- Male
- Humans
- Clinical Trials as Topic
- Cancer Vaccines
- Biotechnology
- 3206 Medical biotechnology
Citation
APA
Chicago
ICMJE
MLA
NLM
Morse, M. A., & Whelan, M. (2010). A year of successful cancer vaccines points to a path forward. Curr Opin Mol Ther, 12(1), 11–13.
Morse, Michael A., and Michael Whelan. “A year of successful cancer vaccines points to a path forward.” Curr Opin Mol Ther 12, no. 1 (February 2010): 11–13.
Morse MA, Whelan M. A year of successful cancer vaccines points to a path forward. Curr Opin Mol Ther. 2010 Feb;12(1):11–3.
Morse, Michael A., and Michael Whelan. “A year of successful cancer vaccines points to a path forward.” Curr Opin Mol Ther, vol. 12, no. 1, Feb. 2010, pp. 11–13.
Morse MA, Whelan M. A year of successful cancer vaccines points to a path forward. Curr Opin Mol Ther. 2010 Feb;12(1):11–13.
Published In
Curr Opin Mol Ther
EISSN
2040-3445
Publication Date
February 2010
Volume
12
Issue
1
Start / End Page
11 / 13
Location
England
Related Subject Headings
- United States
- Prostatic Neoplasms
- Neoplasms
- National Cancer Institute (U.S.)
- Male
- Humans
- Clinical Trials as Topic
- Cancer Vaccines
- Biotechnology
- 3206 Medical biotechnology